Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeloda as Sequential Adjuvant Therapy in High-Risk Breast Cancer
NCT01662128Phase 3Unknown
- Sponsor
- Tianjin Medical University
- Start
- Jun 2012
- Primary completion
- Jun 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in breast cancer, sponsored by Tianjin Medical University. Status: unknown.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01662128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01662128.